Pfizer (NYSE:PFE) Announces Earnings Results

Pfizer (NYSE:PFE) issued its earnings results on Tuesday. The biopharmaceutical company reported $0.77 earnings per share for the quarter, topping the consensus estimate of $0.68 by $0.09, FiscalAI reports. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The business had revenue of $15.03 billion during the quarter, compared to analysts’ expectations of $14.40 billion. During the same period in the prior year, the business earned $0.78 EPS. The business’s revenue for the quarter was up 2.6% compared to the same quarter last year. Pfizer updated its FY 2026 guidance to 2.800-3.000 EPS.

Here are the key takeaways from Pfizer’s conference call:

• Positive Sentiment: Pfizer raised its 2026 revenue guidance midpoint by $500 million to $60.5–$62.5 billion, despite lowering expected COVID revenue to approximately $4 billion. Adjusted EPS guidance was reaffirmed at $2.80–$3.00, absorbing an estimated $0.10 impact from the Innovent transaction.
• Positive Sentiment: The non-COVID business performed strongly, with underlying revenue up 5% operationally and launched and acquired products up 27% excluding prior-year one-time items. Key contributors included Eliquis, Padcev, Vyndaqel, Lorbrena, and Nurtec, while Padcev revenue grew more than 20% following its expanded bladder-cancer indication.
• Positive Sentiment: Pfizer expanded its cost-reduction targets, now expecting approximately $9.7 billion in total net savings through 2029, including additional savings from technology, simplification, and manufacturing optimization. Management said these efforts should support margin expansion while preserving investment in R&D and the dividend.
• Negative Sentiment: The Phase III study of the Seagen-derived SV lung-cancer therapy failed to meet its primary overall-survival endpoint in the overall population, although Pfizer highlighted a benefit in patients who received only one prior line of therapy. The result, along with the removal of Vabryda revenue projections, contributed to $4.3 billion in non-cash intangible-asset impairments and creates additional execution risk for the oncology pipeline.
• Neutral Sentiment: Pfizer emphasized potentially important longer-term catalysts, including its obesity programs, with 10 planned Phase III studies for berobenatide/nirubenatide-related therapies and an initial approval target beginning in 2028. Management also expects multiple regulatory decisions, data readouts, and pivotal study starts over the next 12 months, but these programs remain subject to clinical and regulatory risk.

Pfizer Stock Up 0.6%

PFE stock traded up $0.16 on Wednesday, hitting $25.57. 5,520,906 shares of the company’s stock were exchanged, compared to its average volume of 42,135,168. The firm has a 50 day moving average price of $25.02 and a two-hundred day moving average price of $26.16. Pfizer has a 12-month low of $23.58 and a 12-month high of $28.75. The stock has a market cap of $145.73 billion, a P/E ratio of 19.52 and a beta of 0.34. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.94 and a current ratio of 1.25.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Friday, July 24th will be given a $0.43 dividend. The ex-dividend date of this dividend is Friday, July 24th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.7%. Pfizer’s dividend payout ratio (DPR) is presently 131.30%.

Institutional Investors Weigh In On Pfizer

Several institutional investors have recently added to or reduced their stakes in PFE. Mcguire Capital Advisors Inc. purchased a new position in shares of Pfizer in the fourth quarter worth $64,000. Compound Planning Inc. grew its holdings in shares of Pfizer by 35.5% during the fourth quarter. Compound Planning Inc. now owns 70,555 shares of the biopharmaceutical company’s stock valued at $1,757,000 after buying an additional 18,483 shares during the last quarter. TMB Capital Partners LLC acquired a new position in shares of Pfizer in the 4th quarter valued at $251,000. Axxcess Wealth Management LLC increased its position in shares of Pfizer by 3.3% in the 4th quarter. Axxcess Wealth Management LLC now owns 210,175 shares of the biopharmaceutical company’s stock valued at $5,233,000 after acquiring an additional 6,661 shares during the period. Finally, Birchwood Financial Partners Inc. purchased a new position in Pfizer in the 4th quarter worth $38,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Key Headlines Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Q2 results beat expectations: Pfizer reported adjusted earnings of $0.77 per share versus the $0.68 consensus estimate, while revenue reached $15.03 billion, ahead of the $14.40 billion forecast. Growth from Eliquis, oncology medicines, and other non-COVID products offset weaker pandemic-related sales. Pfizer beats quarterly profit estimates on strong demand for Eliquis
• Positive Sentiment: Revenue outlook improved: Pfizer raised the low end of its 2026 revenue forecast to $60.5 billion from $59.5 billion, maintaining the top end at $62.5 billion. Management also reaffirmed adjusted EPS guidance of $2.80 to $3.00. Pfizer tops quarterly estimates and hikes revenue guidance
• Positive Sentiment: Cost-cutting and pipeline catalysts: Pfizer is targeting an additional $2.5 billion in cost savings by 2029. Separately, positive Phase 3 LITFULO data in vitiligo added support for the company’s growth pipeline, while investors continue to watch its obesity-drug efforts. Pfizer reports positive Phase 3 LITFULO data
• Neutral Sentiment: Recovery remains dependent on newer products: Pfizer’s results suggest its oncology and acquired-product portfolio is becoming a more important growth engine as COVID sales fade. Investors are also monitoring broader pharmaceutical interest in cancer assets, which could increase strategic value for companies with promising oncology pipelines. Pfizer earnings reveal a new engine beyond COVID
• Negative Sentiment: COVID revenue continues to fall: The pandemic portfolio remains a significant headwind, and Pfizer reduced its COVID-product sales expectations. The company also posted a quarterly loss on a reported basis, despite the adjusted earnings beat. PFE Q2 earnings top estimates as COVID forecast is cut

Analysts Set New Price Targets

A number of research firms recently weighed in on PFE. JPMorgan Chase & Co. lowered their price objective on shares of Pfizer from $30.00 to $28.00 and set a “neutral” rating for the company in a research note on Wednesday, July 8th. Weiss Ratings restated a “hold (c)” rating on shares of Pfizer in a report on Monday. Guggenheim lowered their price target on shares of Pfizer from $36.00 to $35.00 and set a “buy” rating for the company in a research report on Monday, July 13th. Wall Street Zen raised shares of Pfizer from a “hold” rating to a “buy” rating in a report on Saturday. Finally, CICC Research initiated coverage on shares of Pfizer in a research note on Thursday, April 16th. They issued an “outperform” rating and a $33.00 price objective for the company. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, fourteen have assigned a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $28.50.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.